Peel Therapeutics a US-based clinical-stage biotech company developing medicines for cancer and inflammatory diseases, announced on Wednesday that it has started a first-in-human clinical study of PEEL-224 in patients with advanced solid tumours.
This move is subsequent to the recent acceptance of the company's Investigational New Drug (IND) Application by the United States Food and Drug Administration (FDA).
The product was produced from a medicine that originates from the leaves and stem of an ancient tree used for thousands of years in traditional Chinese medicine.
The firm is assessing the product in a Phase one dose escalation, repeat-dose, multi-centre, open-label study in patients with advanced solid tumours. The trial is to assess PEEL-224's safety, tolerability, pharmacokinetics and preliminary antitumor activity.
GSK releases decade-long data on Shingrix efficacy
GSK announces positive EAGLE-1 results for gepotidacin in gonorrhoea treatment
Boehringer Ingelheim reports strong growth in 2023 and accelerates late-stage pipeline
Charles River Laboratories launches AMAP to reduce animal testing reliance
PureTech completes enrollment in Phase 2b ELEVATE IPF trial for LYT-100
Cybin secures additional US patent for CYB003 breakthrough therapy programme
UroGen's UGN-103 IND accepted by FDA for bladder cancer treatment
Biophytis reinforces obesity IP with new patent application
MaaT Pharma reveals positive 18-month data for MaaT013 in GI-aGvHD
Fusion Antibodies plc secures contract for OptiPhage library development
Innate Pharma advances Sanofi-developed NK cell engager to Phase 2 for blood cancer patients